Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $130 to $175.
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $130 to $175.